Furthermore , among patients in the top quartile of FGF-23 levels , trandolapril significantly reduced cardiovascular death or incident heart failure ( hazard ratio : 0.45 ; 95 % confidence interval : 0.28 to 0.72 ) , whereas there was no clinical benefit in the remaining patients ( hazard ratio : 1.07 ; 95 % confidence interval : 0.75 to 1.52 ; p interaction = 0.0039 ) .